Pharma News

Biocon Biologics Limited a subsidiary of Biocon Ltd. has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI®, a biosimilar of Aflibercept.

In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU).

Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.

A speech prosthetic developed by a collaborative team of Duke neuroscientists, neurosurgeons, and engineers can translate a person’s brain signals into what they’re trying to say.

Appearing Nov. 6 in the journal Nature Communications, the new technology might one day help people unable to talk due to neurological disorders regain the ability to communicate through a brain-computer interface.

A University of Alberta team has developed a new step to improve the process for creating insulin-producing pancreatic cells from a patient’s own stem cells, bringing the prospect of injection-free treatment closer for people with diabetes.

The researchers take stem cells from a single patient’s blood and chemically wind them back in time, then forward again in a process called “directed differentiation,” to eventually become insulin-producing cells.

Broadly neutralizing antibodies are already being used to fight viruses. This approach could also help to treat infections with multi-resistant bacteria in the future / publication in the renowned journal ‘Cell’

Abbott has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays.

Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.

A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research.

In a recent paper published in Blood, scientists from the University of Birmingham funded by the National Institute for Health and Care Research and the British Heart Foundation have been able to identify how deadly blood clots, in the disease known as Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT), occur.

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.